Capabilities/Facilities

Facility:

In 2015, i3 Pharmaceuticals acquired a 150,000 sqft facility in Warminster, PA.

After substantial capital investment, the facility was commissioned in 2017. As a result of our first ANDA file in 2018, i3 Pharmaceuticals passed its first Prior Approval and GMP inspection.

More than half of the site is dedicated to state-of-the-art pharmaceutical development and manufacturing processes including research and analytical laboratories, pilot and commercial manufacturing plants and warehousing.

Capabilities:

• Product development, manufacturing, packaging and testing
• Pilot Plant sized to promote efficient and reliable scale-up
• Variety of capacities in blending, granulating and tablet coating
• Solvent and aqueous formulations
• High-potency suite

Our Expertise:

• Solid Oral Dosage Forms
• Sustained Release (ER/SR/DR) Formulations
• Poorly Soluble Drugs
• Unstable Molecules
• Potent Compounds
• Bioavailability Enhancement
• Technically Challenging Products